Alma, A Sisram Medical Company, Launches Breakthrough ClearSkin PRO: Doubling the Power of Previous Solutions, Providing Visibly Younger Looking Skin

Food and Healthcare Press Releases Thursday January 30, 2020 16:00
NURNBERG, Germany--30 Jan--PRNewswire/InfoQuest

Alma, one of the top five global leaders of energy-based medical and aesthetics solutions, today announced launch of ClearSkin PRO, a breakthrough applicator featuring twice the power of previous solutions, resulting in visibly younger looking skin.

Unveiled during the IMCAS World Congress in Paris, ClearSkin PRO delivers up to 3000 mJ of non-ablative laser energy per pulse - double the power of existing treatments, to provide proven and remarkable skin rejuvenation results . ClearSkin PRO's unique features include zero downtime, year-round treatments and superior procedure safety for all skin types.

ClearSkin PRO utilizes a non-ablative Er:Glass 1540nm laser with simultaneous contact cooling to create columns of coagulation, promote new dermis synthesis and regenerate the extra cellular matrix while leaving the epidermis intact and maintaining a high level of safety.

Launched together with a new Harmony XL PRO Special Edition, the combination of the two – the long-proven, renewed best-seller multiplatform and the innovative applicator, opens a new era for skin rejuvenation treatments, combining the strongest thermal effect with an already clinically proven array of applicators for holistic treatment approach.

"ClearSkin PRO is a significant evolutionary development, offering enhanced clinical capabilities on top of existing solutions, adding real value to practitioners' clinical portfolio" said Lior Dayan, CEO of Alma.

"ClearSkin PRO definitely offers something unique. Its high level of energy enables much more powerful treatments, and the results are clearly apparent. This is a significant development which adds real value to my clinic, and exceedingly better results for my patients," said Dr. Pablo Naranjo, medical director of Elite laser clinic Madrid, Spain.

About Alma

Alma is a global innovator of Laser, Light-based, Radiofrequency, Plasma and Ultrasound solutions for the aesthetic and surgical markets. We enable practitioners to offer safe and effective procedures while allowing patients to benefit from state-of-the-art, clinically proven technologies and treatments.
For media inquiries, please contact:
ICR Inc.
Edmond Lococo
Tel: +86 (10) 6583-7510

Latest Press Release

Minor Hotels Announces Management of RAKxa Fully Integrative Wellness & Medical Retreat’s Luxury Villas on Bangkok’s Bang Krachao

Minor Hotels, an international hotel owner, operator and investor, has announced a partnership with M.K. Real Estate Development and VitalLife Scientific Wellness Centre (a subsidiary of Bumrungrad International Hospital) to launch RAKxa Fully...

Innatoss Laboratories Launches Neutralizing Antibody Public Testing Service for SARS-CoV-2 in Europe using GenScript's cPass(TM) kit

LEIDEN Netherlands and OSS Netherlands and PISCATAWAY New Jersey--15 Sep--PRNewswire/InfoQuest cPass is first commercially available product to rapidly detect neutralizing antibodies capable of eliminating virus Innatoss Laboratories announced today...

MAGHREB PHARMA Expo to contribute to Algeria plans to export for US$ 5 billion locally produced drugs by 2025

Easyfairs Northeral, the organizer of MAGHREB PHARMA Expo has announced new dates for its annual international tradeshow for the pharmaceutical industry in North Africa. In this context, the Algerian Pharmaceutical Industry Minister, Lotfi Benbahmed,...

Concept Medical announces index patient enrolment in world's first Randomized Controlled Trial with Sirolimus Coated Balloon for the treatment of Superficial Femoral Artery (SFA) in Peripheral Artery Disease

Concept Medical Inc., focused on vascular intervention drug delivery devices, has announced the enrolment of the first patient in the FUTURE SFA (Randomized Controlled Trial of First SirolimUs CoaTed Balloon VersUs StandaRd Balloon Angioplasty in The...

Concept Medical ประกาศรับผู้ป่วยคนแรกเข้าร่วมโครงการวิจัยแรกของโลกที่ดำเนินการแบบสุ่มและมีกลุ่มควบคุม โดยใช้บอลลูนเคลือบยาไซโรลิมัสรักษาหลอดเลือดต้นขาชั้นผิว (SFA) ในผู้ป่วยโรคหลอดเลือดแดงส่วนปลาย

Concept Medical Inc. ผู้เชี่ยวชาญด้านอุปกรณ์นำส่งยาผ่านทางหลอดเลือด ได้ประกาศรับผู้ป่วยรายแรกเข้าร่วมโครงการวิจัย FUTURE SFA (ย่อมาจาก Randomized Controlled Trial of First SirolimUs CoaTed Balloon VersUs StandaRd Balloon Angioplasty in The TrEatment of...

Related Topics